Related Experiment Video
Updated: May 21, 2025

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
Remifentanil use in critically Ill patients requiring mechanical ventilation is associated with increased
Junpei Haruna1, Aki Sasaki2, Satoshi Kazuma3
1Department of Intensive Care Medicine, School of Medicine, Sapporo Medical University, S-1, W-16, Chuo-Ku, Sapporo, Hokkaido, 060-8543, Japan.
Intraoperative remifentanil reduces postoperative delirium incidence, unlike other opioids; however, its efficacy in medical emergencies with organ failure is unknown. We hypothesized that remifentanil use in nonoperative intensive care unit (ICU) patients requiring ventilatory management would improve delirium outcomes. This retrospective study included 95 nonoperative patients with unplanned ICU admissions requiring ventilatory opioids. Delirium was assessed using the Intensive Care Delirium Screening Checklist. Patients were divided into remifentanil and non-remifentanil groups; statistical adjustments were made using propensity score matching and inverse probability weighting. After matching, the remifentanil group had significantly more delirium-free days (DFDs) within 14 days than the non-remifentanil group (8 [5-11] vs. 5 [3-9], p < .001). Adjusted multivariate analysis showed that DFD was significantly increased in the remifentanil group (Odds ratio = 2.639 [95% CI 1.279-5.445]; p = 0.009). Remifentanil use in nonoperative ventilated ICU patients may reduce delirium duration.
Intraoperative remifentanil reduces postoperative delirium incidence, unlike other opioids; however, its efficacy in medical emergencies with organ failure is unknown. We hypothesized that remifentanil use in nonoperative intensive care unit (ICU) patients requiring ventilatory management would improve delirium outcomes. This retrospective study included 95 nonoperative patients with unplanned ICU admissions requiring ventilatory opioids. Delirium was assessed using the Intensive Care Delirium Screening Checklist. Patients were divided into remifentanil and non-remifentanil groups; statistical adjustments were made using propensity score matching and inverse probability weighting. After matching, the remifentanil group had significantly more delirium-free days (DFDs) within 14 days than the non-remifentanil group (8 [5-11] vs. 5 [3-9], p < .001). Adjusted multivariate analysis showed that DFD was significantly increased in the remifentanil group (Odds ratio = 2.639 [95% CI 1.279-5.445]; p = 0.009). Remifentanil use in nonoperative ventilated ICU patients may reduce delirium duration.
More Related Videos
06:04Objective Nociceptive Assessment in Ventilated ICU Patients: A Feasibility Study Using Pupillometry and the Nociceptive Flexion Reflex
Published on: July 4, 2018
04:56In Vitro Method to Control Concentrations of Halogenated Gases in Cultured Alveolar Epithelial Cells
Published on: October 23, 2018
Related Concept Videos
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
REM Sleep Behavior Disorder
RBD is significantly associated with...
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Skeletal Muscle Relaxants: Therapeutic Uses
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Stages of General Anesthesia